TRAW Traws Pharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1130598 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,159.3%
TTM net income YoY90.5%
TTM EPS YoY95.1%
Revenue 3-yr CAGR132.7%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-554.6%
Net margin-467.6%
FCF margin—
EBITDA margin-554.0%
Returns
ROE-1,059.6%
ROA-124.5%
ROIC (approx.)—
Asset turnover0.27x
Leverage & solvency
Liabilities / assets63.5%
Debt / equity0.00x
Current ratio1.22x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio57.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2024Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $2.73M | $57,000 | $56,000 |
| R&D expense | $1.83M | $2.29M | $4.91M | $5.04M | $2.31M | $2.29M | $2.51M | $1.86M |
| SG&A expense | $1.77M | $3.48M | $2.03M | $2.33M | $1.74M | $1.69M | $2.75M | $3.48M |
| Operating income | -$3.60M | -$4.37M | -$6.95M | -$7.37M | -$4.05M | -$1.25M | -$5.20M | -$5.28M |
| Net income | -$3.55M | -$4.21M | -$7.11M | -$7.44M | -$3.96M | -$915,000 | $21.49M | -$29.92M |
| EBITDA | -$3.56M | -$4.32M | -$6.90M | -$7.32M | -$4.04M | -$1.25M | -$5.20M | -$5.28M |
| EPS (basic) | -0.18 | -0.23 | -0.53 | — | -0.34 | -0.11 | 2.17 | — |
| EPS (diluted) | -0.18 | -0.23 | -0.53 | — | -0.34 | -0.11 | 2.09 | — |
| Weighted avg. shares (diluted) | 17.04M | 15.86M | 10.64M | — | 8.82M | 5.82M | 7.22M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $2.34M | $5.02M | $3.13M | $3.82M | $6.42M | $13.08M | $15.94M | $21.34M |
| Receivables | $2.19M | $2.30M | $1.69M | $3.79M | $1.99M | $1.32M | $1.65M | $1.76M |
| Current assets | $4.98M | $7.87M | $5.67M | $7.98M | $9.62M | $15.37M | $18.86M | $24.95M |
| PP&E, net | $5,000 | $5,000 | $6,000 | $7,000 | $7,000 | $8,000 | $9,000 | $10,000 |
| Intangibles | $2.40M | $2.44M | $2.48M | $2.53M | $2.57M | — | — | — |
| Total assets | $7.52M | $10.31M | $8.16M | $10.62M | $12.44M | $15.62M | $19.06M | $24.96M |
| Current liabilities | $9.64M | $9.73M | $13.21M | $11.15M | $7.89M | $7.35M | $10.40M | $11.53M |
| Total liabilities | $9.65M | $9.78M | $13.47M | $11.25M | $7.90M | $7.36M | $13.06M | $56.59M |
| Shareholders' equity | -$2.13M | $535,000 | -$5.31M | -$629,000 | $4.54M | $8.26M | $6.00M | -$31.63M |
| Shares outstanding | 15.38M | 15.26M | 10.16M | 9.07M | 7.13M | 7.07M | 5.08M | 3.65M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.48M | -$7.50M | -$2.58M | -$2.76M | -$4.01M | -$5.98M | -$5.44M | -$4.04M |
| Capital expenditure | — | — | — | $0 | — | — | — | $0 |
| Free cash flow | — | — | — | -$2.76M | — | — | — | -$4.04M |
| Investing cash flow | — | — | — | $0 | — | — | — | $0 |
| Financing cash flow | -$197,000 | $9.39M | $1.90M | $158,000 | -$62,000 | $3.10M | $13,000 | $19.98M |
| Depreciation & amortization | $43,000 | $44,000 | $44,000 | $44,000 | $15,000 | $1,000 | $1,000 | $2,000 |
| Stock-based compensation | $795,000 | $816,000 | $634,000 | $327,000 | $135,000 | $105,000 | $161,000 | $334,000 |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.